scientific presentations and publications

Selected scientific papers and presentations from Cytopia scientists

C. J. BURNS, D. G. BOURKE, L. ANDRAU, X. BU, S. A. Charman, A. C. DONOHUE, E. FANTINO, M. FARRUGIA, J. T. FEUTRILL, M. JOFFE, M. R. KLING, M. KUREK , T. L. NERO, T. NGUYEN, J. T. PALMER, I. PHILLIPS, D. M. Shackleford, H. SIKANYIKA, M. STYLES, S. SU, H. TREUTLEIN , J. SENG, A. F. WILKS 'Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).'  Bioorganic Medicinal Chemistry Letters  2009, 19, 5887-5892.

C.J. BURNS, X. BU , M. F. HARTE, M. JOFFE, H. SIKANYIKA, S. SU, C. E. TRANBERG, Y. WANG, D. Shackleford, S. Charman, A. F. WILKS . 'Discovery of CYT997: a structurally novel orally active microtubule targeting agent.'  Bioorganic Medicinal Chemistry Letters  2009, 19, 4639-4642.

A. Pardanani, T. Lasho, G. SMITH, C. BURNS, E. FANTINO, and A. Tefferi. ‘CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients’ Leukemia. 2009, 23, 1441-5.

N. Williams, R. Bamert, O. Patel, C. Wang, P. Walden, A. F. WILKS, E. FANTINO, J.Rossjohn, I.Lucet. ‘Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domain.’ Journal of Molecular Biology 2009, 387, 219.

K. M. Irvine, K. Schroder, M. Andrews, C. BURNS, S. Su, A. WILKS, D. Hume, M. Sweet. ‘Colony Stimulating Factor-1 (CSF-1) stimulation delivers a pro-atherogenic and publications signal to human macrophages.’ Journal Leukocyte Biology 2009, 85, 278.

C .BURNS, M. HARTE, X. Bu, E. FANTINO, M. Giarrusso, M. JOFFE, M. KUREK, F. Legge, P. Razzino, S. Su, H. TREUTLEIN, S. S. Wan, J. Zeng, A. WILKS. ‘Discovery of 2-(α-Methyl-benzylamino) Pyrazines as Potent Type II Inhibitors of FMS.’ Bioorganic Medicinal Chemistry Letters 2009, 19, 1206.

A. Francesconi, D. Kotasek, M. Burge, G.SMITH, J. Lickliter. ‘Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer.' Journal of Clinical Oncology 2009, 27:15s (suppl: abstr 3568).

J. Lickliter, A. Francesconi, G. SMITH , M. Burge, A. Coulthard, S. Rose, M. Griffin, A. Wilks, D. Wyld, P. Vasey . 'Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer.' Oral presentation at ASCO Meeting in Chicago June 2008. Click here to view abstract (pdf file). Click here to view video of presentation.

M.Ballinger, N.Osman, A.WILKS, S.Su, C.BURNS, X. Bu, P.Little. 'Pyrido-Pyrimidine Derivative CYC10424 Inhibits Glycosaminoglycan Changes on Vascular Smooth Muscle-derived Proteoglycans and Reduces Lipoprotein Binding.' Journal of Cardiovascular Pharmacology. 2008, 52, 403-412.

J.Lickliter, G.SMITH, M.Burge, A.Coulthard, D.Wyld, C.Roberts, G.Parker, P.Vasey. 'Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours.' Abstract from ASCO Meeting in Chicago June 2007. Click here to view abstract (pdf file).

A .WILKS, C. BURNS, G. SMITH, E. FANTINO, I. PHILLIPS, M. MCNALLY, D. BOURKE, L. ANDRAU, N. COURT, P. BUKCZYNSKA, M. JOFFE, A. Tefferi A. Pardanani. T. Lasho, W. Stevenson, O. Cooley. A. Roberts, E. O’Flaherty, T. Bumm, J. Deininger, J. Tyner, M. Deininger. 'A novel JAK2 inhibitor for the treatment of myeloproliferative disorders.' Abstract from AACR Meeting, San Diego Apr 2008. Click here to view abstract (pdf file).

M. HARTE, M. GIARRUSSO, C. BURNS, J. PALMER, L. ANDRAU, P. RAZZINO, S. SU, E. FANTINO, M. JOFFE, S. S. WAN, S. LEGGE, H. TREUTLEIN, A. WILKS, B.Scott, P.Hertzog. Novel Inhibitors of FMS Kinase. Abstract from 6th CHI Protein Kinase Targets Meeting 23-25th June, 2008, Boston, USA. Click here to view abstract (pdf file).

M. Walter, I. Lucet, O. Patel, S. Broughton, R. Bamert, N. Williams, E. FANTINO, A. WILKS, J.Rossjohn. 'The 2.7Å crystal structure of the autoinhibited human c-FMS kinase domain.' Journal of Molecular Biology 2007, 367, 839.

I.Lucet, E. FANTINO, M. STYLES, R. Bamert, O. Patel, S. Broughton, M. Walter, C. J. BURNS, H. TREUTLEIN, A. WILKS, J. Rossjohn. 'The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.' Blood. 2006, 107, 176-83.

K.Irvine, C.BURNS, A.WILKS, S.SU, D.Hume, M.Sweet. 'A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations.' FASEB J. 2006, 20, 1921.

S. LEGGE, A. Budi., H. TREUTLEIN , I. Yarovsky. 'Protein Flexibility: Multiple Molecular Dynamics Simulations of Insulin Chain B.' Biophys. Chem. 2006, 119, 146.

ChemaPhore: Tool for Pragmatic Computer-Aided Structure-Based Drug Design; poster presentation at Drug Discovery Technology Meeting in Boston, August 2005. Click here to view poster (pdf file).

JAK/STAT signaling pathway negatively regulates angiotensin II AT1 receptor induced cardiac hypertrophy in rat cardiomyocytes, Poster presentation at 12th International Conference on Second Messengers and phosphoproteins (SMP 2004) August 3-7, 2004, Montreal, Canada. Click here to view poster (pdf file).

M.Smith, C.Vearing, M.Lackmann, H.TREUTLEIN, J.Himanen, K.Chen, A.Saul, D.Nikolov, W.Boyd. Dissecting the EphA3/Ephrin-A5 Interactions Using a Novel Functional Mutagenesis Screen. J. Biol. Chem., 279, 9522 – 9531, Mar 2004. Click here to view abstract (pdf file).